Previous Article | Next Article 
Journal of Virology, May 1999, p. 3608-3615, Vol. 73, No. 5
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Opposite Effects of SDF-1 on Human Immunodeficiency
Virus Type 1 Replication
Valérie
Maréchal,1
Fernando
Arenzana-Seisdedos,2
Jean-Michel
Heard,1 and
Olivier
Schwartz1,*
Laboratoire Rétrovirus et Transfert
Génétique, URA CNRS 1157,1 and
Unité d'Immunologie Virale, Institut
Pasteur,2 75724 Paris Cedex 15, France
Received 7 October 1998/Accepted 19 January 1999
 |
ABSTRACT |
The
-chemokine SDF-1 binds CXCR4, a coreceptor for human
immunodeficiency virus type 1 (HIV-1), and inhibits viral entry mediated by this receptor. Since chemokines are potent chemoattractants and activators of leukocytes, we examined whether the stimulation of
HIV target cells by SDF-1 affects the replication of virus with
different tropisms. We observed that SDF-1 inhibited the entry of X4
strains and increased the infectivity of particles bearing either a
CCR5-tropic HIV-1 envelope or a vesicular stomatitis virus G envelope.
In contrast to the inhibitory effect of SDF-1 on X4 strains, which is
at the level of entry, the stimulatory effect does not involve
envelope-receptor interactions or proviral DNA synthesis. Rather, we
observed an increased ability of Tat to transactivate the HIV-1 long
terminal repeat in the presence of the chemokine. Therefore, the
effects of SDF-1 on the HIV-1 life cycle can be multiple and opposite,
including both an inhibition of viral entry and a stimulation of
proviral gene expression.
 |
INTRODUCTION |
Chemokines are peptides of 70 to 100 amino acids that activate and induce the migration of leukocytes
(5, 46). They bind to seven transmembrane-spanning, G
protein-coupled receptors. At least two subfamilies, CXC (or
) and
CC (or
) chemokines, are distinguished with respect to the position
of the first two cysteine residues. SDF-1 (stromal cell-derived factor
1) is a CXC chemokine secreted constitutively by several types of cells (5). Functional variants of SDF-1 are generated by
differential splicing of mRNAs. SDF-1
is four amino acids shorter
than SDF-1
at the carboxy terminus. Both species bind with high
affinity to the CXCR4 receptor, which is expressed in many tissues.
SDF-1 stimulates CD34+ cells, pre-B cells, monocytes,
neutrophils, and peripheral blood lymphocytes (PBLs), as indicated by
intracellular [Ca2+] changes and chemotaxis (1, 5,
26, 36). SDF-1 can also induce apoptosis of primary
CD8+ T cells (25). SDF-1 is involved in the
homing of T cells and monocytes (9) and plays a key role in
the development of the embryo. The knockout of the SDF-1 or of the
CXCR4 gene is lethal in mouse embryos, leading to serious developmental
defects of the immune, hematopoietic, circulatory, cardiac, and central
nervous systems (35, 45, 47).
The roles played by chemokines in human immunodeficiency virus
(HIV)-induced pathology are poorly understood. Several chemokine receptors serve as coreceptors for HIV entry into target cells, with a
major role played by CCR5 and CXCR4 (12, 34). The
interaction of gp120, the surface envelope glycoprotein of the virion,
with both CD4 and the coreceptor triggers conformational changes of the
envelope which expose fusogenic epitopes. These events lead to fusion
of the viral and plasma membranes (13, 32).
Macrophage-tropic strains of HIV (now classified as R5 viruses
[7]) replicate in macrophages and in primary
CD4+ T cells and use the CCR5 receptor. T-tropic HIV type 1 (HIV-1) isolates (referred to as X4 viruses) replicate in primary or
established CD4+ lymphocytes and use the CXCR4 receptor.
Viruses isolated in the initial stages of infection use primarily CCR5,
while those isolated from patients with advanced disease use CXCR4 in
addition to, or in place of, CCR5 (16). This observation
suggests that the use of a particular chemokine receptor may have
important consequences for HIV pathogenesis. The CCR5 ligands (the
-chemokines RANTES, MIP-1
, and MIP-1
) and the CXCR4 ligand
SDF-1 inhibit the entry of R5 and X4 viruses, respectively (8, 12,
14, 38). In view of these inhibitory effects, it has been
proposed that an increased production of
-chemokines may protect
against HIV infection and disease progression (14). The
inhibition of HIV entry by chemokines is independent of G protein
signalling pathways and relies both on the occupancy and on the
ligand-induced internalization of the coreceptors (2, 3, 23,
43). However, chemokines may exert a more complex action on HIV
infection, since the
-chemokine RANTES has been reported to increase
viral replication in monocytes or macrophages (29, 39). The
molecular mechanisms of this enhancement are not fully understood. It
is sensitive to pertussis toxin and therefore involves signalling
through Gi proteins (29, 31). It has also been reported that
MIP-1
, MIP-1
, and RANTES increase replication of X4 strains in
PBLs by stimulating the transcription of the CXCR4 gene (19)
or by increasing cell surface colocalization of CD4 and CXCR4
(31). Whether the inhibiting and stimulating effects of
-chemokines, observed in vitro on replicating HIV, have any impact
on the outcome of the in vivo infection is not known.
We have examined the effect of SDF-1 on the in vitro replication of
HIV-1 viruses with various tropisms. We observed that the chemokine
exerts opposite effects on HIV-1 replication, depending on which
receptor is used for entry. SDF-1 inhibited the entry of X4 strains and
increased the infectivity of R5 strains and of vesicular stomatitis
virus G (VSV-G) pseudotypes. In contrast to the inhibitory effect of
SDF-1 on X4 strains, which takes place at the entry level, the
stimulatory effect occurred later in the viral cycle by increasing the
ability of Tat to transactivate the HIV-1 long terminal repeat (LTR).
Therefore, the effects of SDF-1 on the HIV-1 life cycle can be multiple
and opposite, including both the inhibition of viral entry and the
stimulation of provirus transcription.
 |
MATERIALS AND METHODS |
Viruses, cells, and reagents.
HIV-1 (NL43, JRCSF, and NLAD8
strains) and HIV(VSV), a defective HIV-1 with the env gene
deleted and pseudotyped with the VSV-G envelope, were produced, and
infections were performed as described previously (33, 38,
41). The HIV-GFP reporter virus, which encodes the GFP marker in
the place of Nef and has the env gene deleted, was a kind
gift from D. Gabuzda (Dana-Farber Cancer Institute, Boston, Mass.)
(24). HIV-GFP(VSV) was generated like HIV(VSV). The NLAD8
provirus was constructed by introducing a portion of the env
gene from the R5-tropic clone of AD8 into pNL43 and was a kind gift
from E. Freed (National Institute of Allergy and Infectious Diseases,
Bethesda, Md.). P4 cells (HeLa CD4+ CXCR4+
LTR-lacZ) and P4C5 cells (HeLa CD4+
CXCR4+ CCR5+ LTR-lacZ) (3,
33) were grown in Dulbecco modified Eagle medium (DMEM)
supplemented with 10% fetal calf serum. CEMX174 and Jurkat T-cell
lines and U937 and HL60 monocytic cell lines were grown in RPMI 1640 supplemented with 10% fetal calf serum. PBLs were isolated from
healthy, HIV-negative volunteers, stimulated for 3 days with
phytohemagglutinin (PHA) (1 µg/ml; Wellcome), and grown in the
presence of interleukin-2 (IL-2) (3 ng/ml; PeproTech, Inc.). SDF-1
,
referred to in this report as SDF-1, was chemically synthesized
(20) and was a kind gift of F. Baleux (Institut Pasteur,
Paris, France). Bordetella pertussis toxin was purchased from Calbiochem (San Diego, Calif.).
Measurement of HIV infection in P4C5 cells. (i) Single-cycle
assay.
P4C5 cells (104 per well) in 96-well plates
were cultured for 24 h before infection with 200 µl of viral
supernatants (in triplicate) in the absence or in the presence of SDF-1
and with 20 ng of DEAE dextran/ml and 20 mM HEPES buffer (pH 7.3) as
described previously (41). After the indicated periods, the
cells were washed to remove unbound virus. After 24 h,
-gal
activity was measured. The cells were lysed in 100 µl of 60 mM
Na2HPO4, 40 mM NaH2PO4, 10 mM KCl, 10 mM MgSO4, 2.5 mM EDTA, 50 mM
-mercaptoethanol, and 0.125% Nonidet P-40. The lysates were mixed
with 100 µl of 80 mM NaPO4 (pH 7.4), 10 mM
MgCl2, 50 mM
-mercaptoethanol, and 6 mM chlorophenol
red-
-galactopyranoside monoNa salt and incubated at 37°C before
the optical density at 540 nm was measured. The values given are
means ± standard deviations of triplicates. Variations for each
point were less than 10%.
(ii) Study of HIV replication in P4C5 cells.
P4C5 cells
(104 per well) in 96-well plates were cultured for 24 h before infection with 200 µl of viral supernatants (in triplicate) in the absence or in the presence of SDF-1 and with 20 ng of DEAE dextran/ml and 20 mM HEPES buffer (pH 7.3) as described previously (41). The viral inoculum corresponded to 2 and 2.5 ng of p24 for NL43 and JRCSF viruses, respectively. After viral exposure (2 h at
37°C) and every following day, the supernatants were harvested and
replaced with fresh medium containing or not containing SDF-1. Gag p24
concentrations were measured in each supernatant by enzyme-linked immunosorbent assay (ELISA) (Dupont).
Measurement of HIV infection in other cell lines.
For
infections with the HIV-GFP(VSV) reporter virus, 4 × 105 target cells were exposed overnight, with 5 ng of DEAE
dextran/ml, to a viral dose corresponding to 100 ng of p24, in the
absence or in the presence of SDF-1. The cells were washed to remove
unbound virus and further incubated with or without SDF-1 for 8 h.
The cells were then fixed and analyzed by flow cytometry with a
Facscalibur (Becton Dickinson, Mountain View, Calif.) with CellQuest
software. For infection of PBLs, 4 × 105 PBLs per
well in 96-well plates were exposed to 200 µl of viral supernatants
(in duplicate) in the absence or in the presence of SDF-1 and 20 mM
HEPES buffer (pH 7.3). The viral inoculum corresponded to 1 ng of p24
of NLAD8 virus. After 4 h at 37°C, the cells were washed and
resuspended in 200 µl of fresh medium containing 3 ng of IL-2/ml. At
each cell passage, the supernatants were harvested and replaced with
fresh medium containing or not containing SDF-1. Gag p24 concentrations
were measured in each supernatant by ELISA.
Analysis of viral DNA synthesis.
P4 cells (6 × 106) were exposed to the indicated strains of HIV-1 (750 ng
of p24), in the presence or in the absence of SDF-1. Seventeen hours
later, low-molecular-weight DNA was prepared by Hirt extraction,
EcoRI digested, and analyzed by Southern blotting with a
1.9-kb fragment from the pol region of pNL43 as a probe, as
described previously (40).
Measurement of cytosolic Gag p24 amounts.
P4 cells were
preincubated for 20 min in the absence or in the presence of SDF-1 and
exposed to the indicated strains of HIV-1 (300 ng of p24) for 1 h
at 37°C in the absence or in the presence of the chemokine. Cytosolic
fractions were prepared as described previously (33).
Briefly, to remove virus adsorbed at the cell surface, the cells were
incubated for 10 min on ice with 1 ml of pronase (7 mg/ml, freshly
prepared in DMEM with 20 mM HEPES). The cells were resuspended with 1 ml of ice-cold DMEM containing 10% fetal calf serum, washed in
ice-cold phosphate-buffered saline, and resuspended in 2 ml of swelling
buffer (Tris-HCl [pH8], 10 mM; KCl, 10 mM; EDTA, 1 mM) for 15 min at
4°C. The cells were then subjected to mechanical disruption by 15 strokes of a 7-ml
-pestle Dounce homogenizer. Nuclei and unbroken
cells were pelleted at 3,000 rpm for 3 min at 4°C in a Heraeus
Varifuge centrifuge. The resulting postnuclear supernatant was spun at
60,000 rpm in a TL-100 Beckman centrifuge for 10 min at 4°C to
separate the membrane- and vesicle-rich pellet from the cytosolic
supernatant. The supernatant was adjusted to 0.5% Triton X-100 and
analyzed for p24 content by ELISA.
Analysis of LTR activity.
P4 cells were seeded at 8 × 104 per well of a 24-well plate 24 h before
transfection by the Ca phosphate coprecipitation technique. The cells
were transfected with 1 µg of the pLTRX-Luc plasmid, encoding the
luciferase reporter gene driven by the HIV-1 LTR (42), and with or without 30 ng of the pCMV-Tat plasmid,
carrying the tat gene driven by the cytomegalovirus
immediate-early promoter (42). This ratio of pCMV-Tat versus
pLTRX-Luc plasmid was chosen in order to stay in the linear part of the
dose-response curve of Tat activity (42). Six hours after
transfection, the cells were incubated, when stated, with SDF-1 and/or
with pertussis toxin and lysed 18 h later as previously described
(42). Luciferase activity contained in cytoplasmic extracts
was measured with a luminometer (Lumat LB9501; Bertold). The results
are expressed as relative luciferase units (RLU) per µg of cellular
protein and were obtained by subtracting background signal (from
nontransfected cells) from each value and dividing the figure by the
amount of cytoplasmic protein contained in the sample. Experiments were performed in triplicate, and variations for each point were less than
10%.
 |
RESULTS |
Dual effects of SDF-1 on HIV infection.
We examined the
effects of SDF-1 on the replication of HIV in a single-cycle assay by
using the P4C5 indicator cells. P4C5 cells are HeLa cells expressing
the CD4, CXCR4, and CCR5 receptors, and they harbor an integrated
lacZ gene driven by the HIV-1 LTR, which is inducible by the
viral transactivator Tat (3, 33). Upon infection with X4 or
R5 strains of HIV, P4C5 cells produce Tat, and viral replication can be
quantified by using a
-galactosidase (
-gal)-based colorimetric
assay. P4C5 cells were preincubated with SDF-1 (300 nM) for 20 min and
exposed either to the X4 strain NL43 or the R5 strains JRCSF and NLAD8.
As expected,
-gal activity, measured 24 h after exposure to
NL43, was 10-fold lower in the presence of SDF-1 (Fig.
1A), confirming the inhibitory activity of the chemokine on the entry of X4 strains (8, 38). By
contrast,
-gal activity induced by exposure to JRCSF and NLAD8
strains was three- to four-fold higher in the presence of SDF-1
(Fig. 1A). Infections were also performed with HIV-1 particles devoid of gp120 or gp41 and coated with the VSV-G envelope glycoprotein [HIV(VSV)]. VSV-G binds membrane phospholipids, allowing virus entry
independently of the CD4 and chemokine receptors (11). Infection of P4C5 cells with HIV(VSV) was also increased by SDF-1 (Fig.
1A). Thus, stimulation of HIV infection by SDF-1 is independent of
gp120- gp41-mediated binding and entry.

View larger version (35K):
[in this window]
[in a new window]
|
FIG. 1.
Opposite effects of SDF-1 on HIV replication. (A).
Effect of SDF-1 added before virus exposure. P4C5 indicator cells (HeLa
CD4+ CXCR4+ CCR5+
LTR-lacZ+) were preincubated for 20 min in the
absence ( SDF-1) or in the presence (+ SDF-1) of SDF-1 (300 nM) and
exposed to either NL43 (X4 strain), JRCSF and NLAD8 (R5 strains), or
HIV(VSV), a defective HIV-1 with the env gene deleted and
pseudotyped with the VSV-G envelope. Virus doses were 5 ng of p24 for
NL43, JRCSF, or NLAD8 and 1 ng of p24 for HIV(VSV), which is more
infectious (33). After 24 h, the cells were lysed and
-gal activity was measured in the cell extracts. The values are the
means ± standard deviations of triplicates. (B) Dose-response
analysis of the effect of SDF-1. P4C5 cells were preincubated with or
without SDF-1 and exposed to NL43 or to HIV(VSV). After 24 h, the
cells were lysed and -gal activity was measured. For each indicated
concentration of SDF-1, the values are expressed as percent
infectivity, with 100% corresponding to the -gal activity induced
by each virus in the absence of SDF-1. (C) Effect of SDF-1 added after
virus exposure. P4C5 cells were exposed for 2 h to NL43, JRCSF, or
HIV(VSV), and unbound virus was removed. After 16 h, the cells
were incubated with SDF-1 (100 nM), and -gal activity was measured
9 h later. The values are means ± standard deviations of
triplicates. (D) The stimulatory effect of SDF-1 is inhibited by
pertussis toxin. P4 cells were exposed for 2 h to NL43 or
HIV(VSV), and unbound virus was removed. After 16 h, the cells
were incubated for 1 h with or without pertussis toxin (PT) (5 µg/ml). SDF-1 (200 nM) was then added as indicated, and -gal
activity was measured 9 h later. The values are means ± standard deviations of triplicates. Similar results were observed with
P4C5 cells or when smaller amounts of pertussis toxin (50 ng/ml) were
used (not shown). The data are representative of at least three
independent experiments. OD, optical density.
|
|
The extent of the stimulation of viral replication induced by SDF-1 was
examined for various concentrations of the chemokine. The increase of
HIV(VSV) (Fig. 1B) and of R5 strain (not shown) infectivity was dose
dependent and was observed at concentrations as low as 3 to 10 nM.
These nanomolar concentrations are consistent with those inducing the
migration and activation of leukocytes (1, 5, 9, 26) and the
inhibition of X4 strain infection (Fig. 1B).
Since stimulation of HIV replication by SDF-1 is independent of gp120-
or gp41-mediated entry, we examined at which step of
the viral cycle
the chemokine acts. SDF-1 was added 16 h after
virus exposure. At
this period of the cycle, incoming virions
have performed reverse
transcription and proviral DNA has been
integrated in the host
chromosome. P4C5 cells were exposed for
2 h to NL43, JRCSF, or
HIV(VSV); unbound virus was removed; and
16 h later, the cells
were incubated with SDF-1 (100 nM).

-Gal
activity was measured
9 h later (Fig.
1C). The chemokine induced
a two- to fourfold
increase of

-gal activity upon infection with
JRCSF or HIV(VSV),
indicating that SDF-1 stimulates viral replication
when added at a late
step of the viral cycle. Since HIV(VSV) is
a defective pseudotype that
performs only a single cycle of replication,
stimulation was not due to
an effect of SDF-1 at an early step
of a second viral cycle.
Interestingly, under these experimental
conditions, infection with the
X4 strain NL43 was also increased
by SDF-1 (Fig.
1C). Therefore, SDF-1
exerts opposite effects on
the replication of X4 strains: the chemokine
inhibits viral infection
when added before or during virus exposure,
whereas it increases
the efficiency of infection when added at later
steps of the viral
cycle. The stimulatory effect of SDF-1 on HIV
replication was
sensitive to pertussis toxin (Fig.
1D), implicating
Gi-linked
signal transduction pathways in the activity of the
chemokine.
We then examined whether the enhancing effect of SDF-1 could be
observed on multiple rounds of viral replication. P4C5 cells
were
exposed either to the X4 strain NL43 or the R5 strain JRCSF
(with a low
viral inoculum, corresponding to 2 ng of p24) in the
absence or in the
presence of SDF-1 (at 20 or 200 nM) which was
maintained throughout the
study. Viral replication was assessed
by measuring p24 release in cell
supernatants (Fig.
2). The NL43
strain
led to a concentration of 40 ng of p24/ml at day 7 postinfection
(p.i.). As expected, SDF-1 totally inhibited the replication of
the X4
strain at a concentration of 200 nM. The inhibition was
only partial
when the chemokine was used at 20 nM (Fig.
2). The
JRCSF strain
replicated less efficiently than NL43 in P4C5 cells,
and p24
concentrations reached 12 ng/ml at day 7 p.i. The presence
of
SDF-1 induced a dramatic increase of replication of the R5
strain, with
p24 reaching 88 and 173 ng/ml at day 7 p.i. for 20
and 200 nM
SDF-1, respectively (Fig.
2). Therefore, the stimulatory
effect of
SDF-1 on the infectivity of R5 strains could be observed
on both
single-cycle and multiple-round infection assays.

View larger version (9K):
[in this window]
[in a new window]
|
FIG. 2.
Effects of SDF-1 on a multiple-round infection assay of
HIV replication. P4C5 cells were exposed either to the X4 strain NL43
(right panel) or the R5 strain JRCSF (left panel), in the absence ( SDF-1) or in the presence (+ SDF-1) of SDF-1 (at 20 or 200 nM). The
viral inoculum corresponded to 2 and 2.5 ng of p24 for NL43 and JRCSF,
respectively. Viral replication was assessed by measuring p24 release
in cell supernatants at the indicated days p.i. SDF-1 was added to the
cultures after each harvesting in order to maintain the indicated
concentrations of the chemokine. The data are means of triplicates, and
the standard deviation of each experimental point was below 10% (not
shown). The data are representative of two independent experiments.
|
|
SDF-1 does not affect the entry of R5 strains.
We examined the
effect of SDF-1 on the entry of incoming particles by measuring
cytosolic Gag p24 content. We previously reported that the measurement
of cytosolic p24 soon after virus exposure is a reliable assay for the
assessment of virus entry events leading to authentic cell infection
(33). P4C5 cells were incubated for 1 h at 37°C with
the NL43, NLAD8, or JRCSF strain in the absence or the presence of
SDF-1 (200 nM). The chemokine was added 20 min before virus exposure in
order to allow binding to CXCR4. Cytosolic Gag p24 contents were
measured after virus exposure (Fig. 3A).
SDF-1 induced a fourfold decrease in cytosolic p24 content detected
upon exposure to the X4 strain NL43 (Fig. 3A). This observation
confirmed that the chemokine inhibits the entry of the X4 strain. In
contrast, SDF-1 did not significantly affect the cytosolic p24 contents
after exposure to the R5 strains NLAD8 and JRCSF (Fig. 3A). Therefore,
the enhanced infection with R5 strains in the presence of SDF-1 is not
a consequence of a more efficient entry.

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 3.
Analysis of the effect of SDF-1 on cytosolic Gag p24
content and proviral DNA synthesis in target cells and on LTR activity.
(A) Cytosolic Gag p24 content. P4C5 cells were preincubated for 20 min
with (+ SDF-1) or without ( SDF-1) SDF-1 (200 nM) and exposed to the
indicated viruses (with a dose of 300 ng of p24) for 1 h at
37°C. The cells were treated with pronase, to eliminate virus
adsorbed at the cell surface, and lysed. Postnuclear supernatants were
separated into cytosol and pellet fractions. The pellet fraction
corresponds to cellular membranes and vesicles. Gag p24 content was
measured in the cytosolic fraction. (B) Synthesis of proviral DNA in
newly infected cells. P4C5 cells were preincubated for 30 min with (+)
or without ( ) SDF-1 (200 nM) and exposed to the indicated viruses
(with a dose of 750 ng of p24). Seventeen hours later,
low-molecular-weight DNA was extracted and analyzed by Southern
blotting with an HIV probe from the pol region. Samples were
digested with EcoRI, which produced, for NL43, diagnostic
fragments with sizes of 5.7 and 9.1 kb from viral linear (L) and one
LTR circular (C) DNA, respectively. The HIV(VSV) pseudotype generated
two fragments: a 5.7-kb linear species and a 7.8-kb circular species.
JRCSF, whose genome does not contain an EcoRI site, yielded
a 9.7-kb signal corresponding to full-length proviral DNA. Samples were
also hybridized with a probe corresponding to the mitochondrial gene
coding for cytochrome b to verify that similar amounts of
low-molecular-weight DNA were loaded in each lane (not shown). (C)
Effect of SDF-1 on HIV-1 LTR activity. P4 cells were transfected with 1 µg of pLTRX-Luc, with or without 30 ng of pCMV-Tat DNA. After 6 h, the cells were incubated in the absence or in the presence of SDF-1
(200 nM), and 18 h later luciferase activities were measured in
cell extracts. Where indicated, pertussis toxin (PT) (50 ng/ml) was
added simultaneously with SDF-1. Similar results were observed at
higher doses of pertussis toxin (5 µg/ml [not shown]). The data are
representative of three independent experiments.
|
|
SDF-1 does not affect the efficiency of reverse transcription.
The amount of newly reverse-transcribed proviral DNA was monitored.
P4C5 cells were preincubated for 30 min at 37°C with or without SDF-1
(200 nM) and exposed to either the NL43, HIV(VSV), or JRCSF viral
strain, in the presence or in the absence of the chemokine.
Nonintegrated viral DNA was extracted 17 h later and analyzed by
Southern blotting with a probe from the pol region (Fig.
3B). Samples were digested with EcoRI, which, in the case of
NL43, produced diagnostic fragments of 5.7 and 9.1 kb for viral linear
(L) DNA and one LTR circular (C) DNA, respectively (40). The
HIV(VSV) pseudotype generated two fragments: a 5.7-kb linear species
and a 7.8-kb circular species, shorter than that of NL43 due to the
deletion in the env gene. JRCSF, whose genome does not
contain an EcoRI site, yielded a 9.7-kb signal corresponding to full-length proviral DNA. No signal was detected when target cells
were treated with zidovudine, indicating that the hybridizing DNA was
actually de novo synthesized during the infection period (not shown).
The detection of the NL43-specific DNA signal was greatly reduced in
the presence of SDF-1 (Fig. 3B), confirming the block of X4 strain
entry by the chemokine (8, 38). In contrast, SDF-1 did not
significantly affect proviral DNA synthesis of the HIV(VSV) or JRCSF
strains. Viral DNA molecules undergoing circularization after their
transport to the nucleus were used as markers to monitor nuclear import
of preintegration complexes (10). For HIV(VSV), the ratios
of circular DNA to total viral DNA were equivalent with and without
SDF-1. Thus, SDF-1 did not significantly affect the efficiency of
proviral DNA synthesis and subsequent nuclear import of preintegration
complexes. This observation was confirmed in three independent
experiments and by quantitative analysis of hybridization signal
intensity by phosphorimager scanning (not shown). Increased HIV
infectivity by SDF-1 is therefore not due to an enhancement of viral
entry or of the reverse transcription process.
SDF-1 increases Tat-mediated provirus transcription.
We
investigated whether SDF-1 acts at a late step of the viral cycle
by increasing Tat-mediated transactivation of the HIV-1 LTR. HeLa-CD4
cells were transiently cotransfected with the pLTRX-Luc plasmid, which
contains the luciferase reporter gene driven by the HIV-1
LTR, and with a Tat expression vector (pCMV-Tat). Six hours after the
addition of DNA, the cells were incubated in the presence or in the
absence of SDF-1 (200 nM), and luciferase activity was measured 18 h later (Fig. 3C). In the absence of SDF-1, the LTR promoter yielded a
baseline luciferase activity of 6 RLU, which rose to 690 RLU upon
transfection of the pCMV-Tat DNA. The baseline activity of the LTR
(without Tat) was not significantly increased by SDF-1 and reached 9 RLU. In the presence of Tat, luciferase activity was significantly
higher in SDF-1-treated cells and rose to 2,000 RLU (Fig. 3C). This
stimulation corresponded, in four independent experiments, to a mean
increase of luciferase activity of (3.1 ± 0.5)-fold in the
presence of SDF-1 (not shown). We then examined whether pertussis toxin
inhibited the effect of SDF-1 on Tat transactivation. In the absence of
SDF-1, equivalent levels of luciferase activity were measured with and
without pertussis toxin (Fig. 3C), indicating that the compound did not
affect the ability of the LTR to be transactivated by Tat. However, the
toxin abrogated the stimulatory effects of SDF-1 (Fig. 3C). Altogether, these experiments indicated that SDF-1 stimulates Tat-mediated transcription through a mechanism involving Gi-linked signal
transduction pathways.
Stimulatory effects of SDF-1 in monocytic and lymphoid cells.
With the aim of analyzing the effect of SDF-1 on a single round of
viral infection in monocytic and lymphoid cell lines, experiments were
performed with a VSV-G pseudotype of the HIV-GFP reporter virus. This
defective recombinant virus contains a deletion in the env
gene and encodes the GFP marker protein in place of Nef (24). Infected cells can be detected by measuring GFP
expression by flow cytometry. HeLa CD4 cells, U937 and HL60 monocytic
cell lines, and CEMX174 and Jurkat lymphoid cells were exposed to
equivalent viral inocula (100 ng of p24). The proportion of
GFP-expressing cells, measured 24 h later, varied from 12 to 23%
(Fig. 4). In contrast, the HUT78 lymphoid
cell line and PBLs stimulated by PHA and grown in the presence of IL-2
were poorly infected by HIV-GFP(VSV) (<1% GFP-expressing cells [not
shown]). This experiment showed that susceptibility to HIV-GFP(VSV)
infection varies from one cell line to another. The effect of SDF-1 on
HIV replication was then studied in susceptible cell lines. In HeLa
cells, in U937 and HL60 monocytic cells, and in CEMX174 lymphoid cells, the proportion of GFP-expressing cells was higher when infections were
performed in the presence of SDF-1 (Fig. 4). No effect was observed in
Jurkat cells (Fig. 4). In MT4 lymphoid cells, exposure to HIV-GFP(VSV)
led to 85% GFP+ cells, and this proportion was not
increased by the chemokine (not shown). These experiments showed that
SDF-1 increases the efficiency of HIV infection in a variety of cell
lines, including HeLa CD4, U937, HL60, and CEMX174, whereas others,
such as Jurkat and MT4, are not sensitive to the chemokine.

View larger version (36K):
[in this window]
[in a new window]
|
FIG. 4.
Analysis of HIV-1 infection in the presence of SDF-1 in
various cell lines. HeLa CD4 cells (clone P4), U937 and HL60 monocytic
cells, and CEMX174 and Jurkat lymphoid cell lines were infected with
the HIV-GFP defective virus pseudotyped with the VSV-G envelope, which
contains, in place of nef, the gene coding for GFP.
Following integration and proviral expression, the cells synthetize
GFP, which can be detected by flow cytometry. The cell lines were
exposed to HIV-GFP(VSV) (100 ng of p24) with (+ SDF-1) or without
( SDF-1) SDF-1 (200 nM). After an overnight incubation, the cells
were washed to remove unbound virus and further incubated with or
without SDF-1 for 8 h. Infection was then revealed by flow
cytometry analysis on gated living cells. The values are presented as
two-color dot blots, with the green fluorescence (GFP) on the abscissa
and the red fluorescence on the ordinate. The percentage of
GFP+ cells is indicated in each panel. In the absence of
viral infection, these percentages were <1% (not shown). The data are
representative of three independent experiments.
|
|
Replication-competent virus was then used to study the effect of SDF-1
on HIV replication in PBLs. PHA-stimulated PBLs from
six different
donors were exposed to the R5 strain NLAD8 in the
presence or in the
absence of SDF-1. Viral replication was monitored
by a time course
measurement of p24 concentrations in cell supernatants.
In two donors,
we observed a two- to threefold increase of p24
levels when infection
was performed in the presence of SDF-1.
No significant effect of SDF-1
was observed in PBLs from four
other donors. Representative examples of
responsive and unresponsive
donors is shown Fig.
5 (donors A and B, respectively).

View larger version (9K):
[in this window]
[in a new window]
|
FIG. 5.
Analysis of HIV-1 replication in the presence of SDF-1
in PBLs. PHA-stimulated PBLs (from six different donors) were exposed
to the R5 strain NLAD8 (viral inoculum corresponding to 1 ng of p24) in
the presence (+ SDF-1) or in the absence ( SDF-1) of SDF-1 (200 nM).
Viral replication was assessed by measuring p24 release in cell
supernatants at the indicated days p.i. SDF-1 was added to the cultures
after each harvesting in order to maintain the indicated concentrations
of the chemokine. The values are means ± standard deviations of
duplicates. In two of the donors, we observed a two- to threefold
increase of p24 levels when infection was performed in the presence of
SDF-1. A representative example of a responsive donor is provided in
the left panel (donor A). No significant effect of SDF-1 was observed
in PBLs from four other donors. An example of an unresponsive donor is
donor B (right panel).
|
|
 |
DISCUSSION |
By binding to its receptor, CXCR4, the
-chemokine SDF-1
interferes with the entry of X4 HIV strains into target cells (8, 38) (Fig. 1 and 3). We show here that this chemokine exerts an
additional and opposite effect on infection by both X4 and R5 viruses
by enhancing Tat-mediated transcriptional activity of the HIV LTR.
Several lines of evidence indicate that the enhancement of HIV-1
infection by SDF-1 takes place at a late stage of the viral cycle
rather than at the level of entry. First, the chemokine increased to
the same extent the infectivities of R5 strains and viruses pseudotyped
with the VSV-G envelope, indicating that enhancement is independent of
gp120- or gp41-mediated entry. Second, time course experiments showed
that SDF-1 was equally efficient when added 16 h after virus
exposure, confirming that the positive effect of SDF-1 is not due to a
modification of the number or of the localization of coreceptors at the
cell surface. Moreover, under these experimental conditions, infection
with both X4 and R5 strains was increased by SDF-1. Third, a direct
analysis of entry events showed that SDF-1 inhibited cytosolic Gag p24
uptake and proviral DNA synthesis of X4 strains when added before virus exposure but had no significant effects on R5 strains and on
VSV-G-pseudotyped viruses. Lastly, evidence was obtained for an
increased transactivation by Tat of the HIV LTR in the presence of
SDF-1. Interestingly, the extent of the stimulation of transcriptional
activity of the viral promoter (three- to fourfold) was in the same
range as that of viral infectivity. This suggests that the positive
effect of SDF-1 on HIV infection is mainly, if not only, due to
stimulation of proviral gene expression.
Other cytokines have dichotomous effects on the viral cycle. Tumor
necrosis factor alpha (TNF-
), transforming growth factor
(TGF-
), gamma interferon (IFN-
), IL-4, IL-10, and IL-13 also exert positive and negative effects on HIV infection (15, 37, 44). Some of these effects vary according to the timing of HIV infection and include cellular activation and upregulation of coreceptor expression. The
-chemokines RANTES, MIP-1
, and
MIP-1
can increase HIV replication in monocytes, macrophages, and
lymphocytes, although their major effect is to inhibit the entry of R5
strains (19, 29, 31, 39). The positive effects of
-chemokines are pertussis toxin sensitive (29, 31). Dolei
et al. suggested that
-chemokines may increase the entry of X4
strains into PBLs as a consequence of an accumulation of CXCR4
transcripts (19). However, no evidence of modified CXCR4
surface levels was provided in that study. Recently, Kinter et al.
reported that
-chemokines have no effect on CXCR4 cell surface
levels but increase surface colocalization of CD4 and CXCR4
(31). The mechanisms producing positive effects of
-chemokines on HIV replication are therefore not yet fully understood.
We show here that increases of HIV infectivity and of LTR activity
induced by SDF-1 were sensitive to pertussis toxin, implying that
cellular Gi-linked signal transduction pathways mediate the action of
the chemokine. The signaling pathways activated by chemokine receptors
are multiple and not fully understood (5, 22, 46). Chemokine
receptors couple to members of the Gi or Gq family of G proteins.
SDF-1, like other chemokines, induces phosphorylation of its receptor
and stimulates G protein activation, inositol phosphate generation, and
calcium elevation (22, 23, 46). Downstream events include
the tyrosine kinases Pyk2 and mitogen-activated protein kinase and
phosphatidylinositol 3-kinase (18, 28, 46). Furthermore,
chemokines may upregulate transcription factors, such as nuclear
transcription factor
B, which may, in turn, augment HIV
transcription (22, 30). By using an HIV-GFP(VSV) reporter virus, we show here that the positive effect of SDF-1 on HIV infection is observed not only in HeLa-derived indicator cells but also in U937
and HL60 monocytic cells and in CEMX174 lymphoid cells. In contrast,
cell lines like Jurkat or MT4 were not susceptible, although they
express surface CXCR4 molecules fully functional for HIV entry.
However, there are several indications that a dissociation exists
between HIV binding and signalling through chemokine receptors. First,
deletion of the C-terminal cytoplasmic domain of CXCR4 or of CCR5 does
not affect HIV entry, although it alters chemokine-induced receptor
downregulation (2, 3, 23, 43). Second, SDF-1 analogs, which
act as CXCR4 antagonists, do not promote Ca2+ intracellular
changes although they retain their anti-HIV activity (17,
27). Third, the function of CCR5 as an HIV-1 coreceptor is not
related to its ability to signal or to be desensitized upon ligand
binding (4, 21). It is therefore conceivable that in Jurkat
or MT4 T cells, CXCR4 allows virus entry but does not activate
signalling pathways leading to an enhancement of Tat activity.
We also studied the effect of SDF-1 in primary lymphocytes. A
significantly increased replication of R5 strains was observed in cells
from two of the six analyzed donors, whereas no effect was detected in
the others (Fig. 5). This inconsistent effect of SDF-1 does not argue
against the relevance of the phenomenon in the natural target cells of
HIV replication. Indeed, primary cell populations are heterogeneous,
possibly containing various proportions of cells susceptible to the
effect of SDF-1 on HIV infection. This could mask the effects observed
in homogeneous, immortalized cell clones. Crude supernatants from PBL
cultures also contain variable levels of numerous cytokines which are
either stimulators or inhibitors of HIV replication (15).
Stimulatory cytokines include IL-1
, IL-2, IL-3, IL-6, IL-12, TNF-
and TNF-
, and the macrophage and granulocyte-macrophage
colony-stimulating factors. IFN-
and IFN-
suppress HIV
replication, whereas TGF-
, IL-4, IL-10, IL-13, and IFN-
either
induce or suppress HIV expression, depending on the culture system
(15). Inconsistent effects in PBLs may therefore reflect
variations in the relative levels of endogenous cytokines or other
unidentified factors. Interestingly, Kinter et al. also observed
donor-to-donor variability with regard to the stimulatory activity of
-chemokines on HIV replication in primary CD4+ T cells
(31).
The in vivo relevance of the positive effect of SDF-1 on HIV
replication is a matter for speculation. The pathogenesis of HIV is
multifactorial and is influenced by both viral and host factors
(15). The multifactorial nature of HIV pathogenesis is
reflected in the highly variable rates of disease progression which are
observed in infected individuals. Since a huge number of replication
cycles is required for disease progression, even a three- to fourfold
increase in the efficiency of the viral cycle could have significant
effects on virus loads. Disease progression is associated with a shift
in chemokine receptor usage, from CCR5 to CXCR4 (16).
Whether this shift is induced by the chemokines themselves and/or by
other host or viral factors is not known. The relative influence of the
positive and negative effects of the
-chemokines and of SDF-1 on HIV
replication in vivo remains unknown. A delicate balance among a wide
array of host positive and negative factors, including chemokines,
likely determines the net rate of viral replication in HIV-infected
individuals (15). The stimulating activity of chemokines
should also be taken into account when considering the use of chemokine
analogs as anti-HIV agents (6, 12).
 |
ACKNOWLEDGMENTS |
We thank Susan Michelson for critical reading of the manuscript
and F. Baleux, D. Gabuzda, E. Freed, N. Landau, and A. Miyanohara for
the kind gift of reagents.
This work was supported by grants from the Agence Nationale de
Recherche sur le SIDA (ANRS) and the Pasteur Institute.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Laboratoire
Rétrovirus et Transfert Génétique, URA CNRS 1157, Institut Pasteur, 28 rue du Dr. Roux, 75724 Paris Cedex 15, France.
Phone: 33 (1) 45 68 83 53. Fax: 33 (1) 45 68 89 40. E-mail:
schwartz{at}pasteur.fr.
 |
REFERENCES |
| 1.
|
Aiuti, A.,
I. J. Webb,
C. Bleul,
T. Springer, and J. C. Gutierrez-Ramos.
1997.
The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitor to peripheral blood.
J. Exp. Med.
185:111-120[Abstract/Free Full Text].
|
| 2.
|
Alkhatib, G.,
M. Locati,
P. E. Kennedy,
P. M. Murphy, and E. A. Berger.
1997.
HIV-1 coreceptor activity of CCR5 and its inhibition by chemokines: independence from G protein signaling and importance of coreceptor downmodulation.
Virology
234:340-348[Medline].
|
| 3.
|
Amara, A.,
S. Le Gall,
O. Schwartz,
J. Salamero,
M. Montes,
P. Loetscher,
M. Baggioloni,
J. L. Virelizier, and F. Arenzana-Seisdedos.
1997.
HIV co-receptor down-regulation as anti-viral principle. SDF-1 dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication.
J. Exp. Med.
186:139-146[Abstract/Free Full Text].
|
| 4.
|
Aramori, I.,
S. S. Ferguson,
P. D. Bieniasz,
J. Zhang,
B. Cullen, and M. G. Cullen.
1997.
Molecular mechanism of desensitization of the chemokine receptor CCR-5: receptor signaling and internalization are dissociable from its role as an HIV-1 co-receptor.
EMBO J.
16:4606-4616[Medline].
|
| 5.
|
Baggiolini, M.,
B. Dewald, and B. Moser.
1997.
Human chemokines: an update.
Annu. Rev. Immunol.
15:675-705[Medline].
|
| 6.
|
Baggiolini, M., and B. Moser.
1997.
Blocking chemokine receptors.
J. Exp. Med.
186:1189-1191[Free Full Text].
|
| 7.
|
Berger, E. A.,
R. W. Doms,
E. M. Fenyö,
B. T. M. Korber,
D. R. Littman,
J. P. Moore,
Q. J. Sattentau,
H. Schuitemaker,
J. Sodroski, and R. A. Weiss.
1998.
A new classification for HIV-1.
Nature
391:240[Medline].
|
| 8.
|
Bleul, C. C.,
M. Farzan,
H. Choe,
C. Parolin,
Y. Clarck-Lewis,
J. Sodroski, and T. A. Springer.
1996.
The lymphocyte chemo-attractant SDF-1 is a ligand for lestr/fusin and blocks HIV-1 entry.
Nature
382:829-833[Medline].
|
| 9.
|
Bleul, C. C.,
R. C. Fuhlbrigge,
J. M. Casasnovas,
A. Aiuti, and T. A. Springer.
1996.
A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1).
J. Exp. Med.
184:1101-1109[Abstract/Free Full Text].
|
| 10.
|
Brown, P. O.,
B. Bowerman,
H. E. Varmus, and J. M. Bishop.
1987.
Correct integration of retroviral DNA in vitro.
Cell
49:347-356[Medline].
|
| 11.
|
Burns, J. C.,
T. Friedmann,
W. Driever,
M. Burrascano, and J.-K. Yee.
1993.
Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells.
Proc. Natl. Acad. Sci. USA
90:8033-8037[Abstract/Free Full Text].
|
| 12.
|
Cairns, J. S., and M. P. D'Souza.
1998.
Chemokines and HIV-1 second receptors: the therapeutic connection.
Nat. Med.
4:563-568[Medline].
|
| 13.
|
Clapham, P. R.
1997.
HIV and chemokines: ligands sharing cell-surface receptors.
Trends Cell Biol.
7:264-268.
[Medline] |
| 14.
|
Cocchi, F.,
A. L. DeVico,
A. Garzino-Demo,
S. K. Arya,
R. C. Gallo, and P. Lusso.
1995.
Identification of RANTES, MIP-1 , and MIP-1 as the major HIV-suppressive factors produced by CD8+ T cells.
Science
270:1811-1815[Abstract/Free Full Text].
|
| 15.
|
Cohen, O. J.,
A. Kinter, and A. S. Fauci.
1997.
Host factors in the pathogenesis of HIV disease.
Immunol. Rev.
159:31-48[Medline].
|
| 16.
|
Connor, R. I.,
K. E. Sheridan,
D. Ceradini,
S. Choe, and N. R. Landau.
1997.
Change in coreceptor use correlates with disease progression in HIV-1-infected individuals.
J. Exp. Med.
185:621-628[Abstract/Free Full Text].
|
| 17.
|
Crump, M. P.,
J. H. Gong,
P. Loetscher,
K. Rajarathnam,
A. Amara,
F. Arenzana-Seisdedos,
J. L. Virelizier,
M. Baggiolini,
B. D. Sykes, and I. Clark-Lewis.
1997.
Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1.
EMBO J.
16:6996-7007[Medline].
|
| 18.
|
Davis, C. B.,
I. Dikic,
D. Unutmaz,
C. M. Hill,
J. Arthos,
M. A. Siani,
D. A. Thompson,
J. Schlessinger, and D. R. Littman.
1997.
Signal transduction due to HIV-1 envelope interactions with chemokine receptors CXCR4 or CCR5.
J. Exp. Med.
186:1793-1798[Abstract/Free Full Text].
|
| 19.
|
Dolei, A.,
A. Biolchini,
C. Serra,
S. Curreli,
E. Gomes, and F. Dianzani.
1998.
Increased replication of T-cell tropic HIV strains and CXCR4 induction in T cells treated with MIP-1 , MIP-1 and RANTES chemokines.
AIDS
12:183-190[Medline].
|
| 20.
|
Dumonceaux, J.,
S. Nisole,
C. Chanel,
L. Quivet,
A. Amara,
F. Baleux,
P. Briand, and U. Hazan.
1998.
Spontaneous mutations in the env gene of the human immunodeficiency virus type 1 NDK isolate are associated with a CD4-independent entry phenotype.
J. Virol.
72:512-519[Abstract/Free Full Text].
|
| 21.
|
Farzan, M.,
H. Choe,
K. A. Martin,
Y. Sun,
M. Sidelko,
C. R. Mackay,
N. P. Gerard,
J. Sodroski, and C. Gerard.
1997.
HIV-1 entry and macrophage inflammatory protein 1beta-mediated signaling are independent functions of the chemokine receptor CCR5.
J. Biol. Chem.
272:6854-6857[Abstract/Free Full Text].
|
| 22.
|
Ganju, R. K.,
S. A. Brubaker,
J. Meyer,
P. Dutt,
Y. M. Yang,
S. X. Qin,
W. Newman, and J. E. Groopman.
1998.
The alpha-chemokine, stromal cell-derived factor-1 alpha, binds to the transmembrane G-protein-coupled CXCR-4 receptor and activates multiple signal transduction pathways.
J. Biol. Chem.
273:23169-23175[Abstract/Free Full Text].
|
| 23.
|
Haribabu, B.,
R. M. Richardson,
I. Fisher,
S. Sozzani,
S. C. Peiper,
R. Horuk,
H. Ali, and R. Snyderman.
1997.
Regulation of human chemokine receptors CXCR4. Role of phosphorylation in desensitization and internalization.
J. Biol. Chem.
272:28726-28731[Abstract/Free Full Text].
|
| 24.
|
He, J.,
Y. Chen,
M. Farzan,
H. Choe,
A. Ohagen,
S. Gartner,
J. Busciglio,
X. Yang,
W. Hofmann,
W. Newmann,
C. R. Mackay,
J. Sodroski, and D. Gabuzda.
1997.
CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia.
Nature
385:645-649[Medline].
|
| 25.
|
Herbein, G.,
U. Mahlknecht,
F. Batliwalla,
P. Gregersen,
T. Pappas,
J. Butler,
W. A. O'Brien, and E. Verdin.
1998.
Apoptosis of CD8(+) T cells is mediated by macrophages through interaction of HIV gp120 with chemokine receptor CXCR4.
Nature
395:189-194[Medline].
|
| 26.
|
Hesselgesser, J.,
M. Liang,
J. Hoxie,
M. Greenberg,
L. F. Brass,
M. J. Orsini,
D. Taub, and R. Horuk.
1998.
Identification and characterization of the CXCR4 chemokine receptor in human T cell lines: ligand binding, biological activity, and HIV-1 inefectivity.
J. Immunol.
160:877-883[Abstract/Free Full Text].
|
| 27.
|
Heveker, N.,
M. Montes,
L. Germeroth,
A. Amara,
A. Trautmann,
M. Alizon, and J. Schneider-Mergener.
1998.
Dissociation of the signalling and antiviral properties of SDF-1-derived small peptides.
Curr. Biol.
8:369-376[Medline].
|
| 28.
|
Jones, S. A.,
B. Moser, and M. Thelen.
1995.
A comparison of post-receptor signal transduction events in Jurkat cells transfected with either IL-8R1 or IL-8R2. Chemokine mediated activation of p42/p44 MAP-kinase (ERK-2).
FEBS Lett.
364:211-214[Medline].
|
| 29.
|
Kelly, M. D.,
H. M. Naif,
S. L. Adams,
A. L. Cunningham, and A. R. Lloyd.
1998.
Dichotomous effects of -chemokines on HIV replication in monocytes and monocyte-derived macrophages.
J. Immunol.
160:3091-3095[Abstract/Free Full Text].
|
| 30.
|
Kingsman, S. M., and A. J. Kingsman.
1996.
The regulation of human immunodeficiency virus type-1 gene expression.
Eur. J. Biochem.
240:491-507[Medline].
|
| 31.
|
Kinter, A.,
A. Catanzaro,
J. Monaco,
M. Ruiz,
J. Justement,
S. Moir,
J. Arthos,
A. Oliva,
L. Ehler,
S. Mizell,
R. Jackson,
M. Ostrowski,
J. Hoxie,
R. Offord, and A. S. Fauci.
1998.
CC-chemokines enhance the replication of T-tropic strains in CD4+ T cells: Role of signal transduction.
Proc. Natl. Acad. Sci. USA
95:11880-11885[Abstract/Free Full Text].
|
| 32.
|
Kwong, P. D.,
R. Wyatt,
J. Robinson,
R. Sweet,
J. Sodroski, and W. A. Hendrickson.
1998.
Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody.
Nature
393:648-659[Medline].
|
| 33.
|
Maréchal, V.,
F. Clavel,
J. M. Heard, and O. Schwartz.
1998.
Cytosolic Gag p24 as an index of productive entry of human immunodeficiency virus type 1.
J. Virol.
72:2208-2212[Abstract/Free Full Text].
|
| 34.
|
Moore, J. P.,
A. Trkola, and T. Dragic.
1997.
Co-receptors for HIV-1 entry.
Curr. Opin. Immunol.
9:551-562[Medline].
|
| 35.
|
Nagasawa, T.,
S. Hirota,
K. Tachibana,
N. Takakura,
S. Nishikawa,
Y. Kitamura,
N. Yoshida,
H. Kikutani, and T. Kishimoto.
1996.
Defects of B-cell lymphopoiesis and bone marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1.
Nature
382:635-638[Medline].
|
| 36.
|
Nagasawa, T.,
H. Kikutani, and T. Kishimoto.
1994.
Molecular cloning and structure of a pre-B cell growth-stimulating factor.
Proc. Natl. Acad. Sci. USA
91:2305-2309[Abstract/Free Full Text].
|
| 37.
|
Naif, H. M.,
S. Li,
M. Ho-Shon,
J. M. Mathijs,
P. Williamson, and A. L. Cunningham.
1997.
The state of maturation of monocytes into macrophages determines the effects of IL-4 and IL-13 on HIV replication.
J. Immunol.
158:501-506[Abstract].
|
| 38.
|
Oberlin, E.,
A. Amara,
F. Bachelerie,
C. Bessia,
J. L. Virelizier,
F. Arenzana-Seisdedos,
O. Schwartz,
J. M. Heard,
I. Clark-Lewis,
D. F. Legler,
M. Loetscher,
M. Baggiolini, and B. Moser.
1996.
The CXC chemokine, stromal cell derived factor 1 (SDF-1), is the ligand for LESTR/fusin and prevents infection by lymphocyte-tropic HIV-1 syncytium-inducing strains.
Nature
382:833-835[Medline].
|
| 39.
|
Schmidtmayerova, H.,
B. Sherry, and M. Bukrinsky.
1996.
Chemokines and HIV replication.
Nature
382:767[Medline].
|
| 40.
|
Schwartz, O.,
V. Maréchal,
O. Danos, and J. M. Heard.
1995.
Human immunodeficiency virus type 1 Nef increases the efficiency of reverse transcription in the infected cell.
J. Virol.
69:4053-4059[Abstract].
|
| 41.
|
Schwartz, O.,
V. Marechal,
B. Friguet,
F. Arenzana-Seisdedos, and J. M. Heard.
1998.
Antiviral activity of the proteasome on incoming HIV-1.
J. Virol.
72:3845-3850[Abstract/Free Full Text].
|
| 42.
|
Schwartz, O.,
J. L. Virelizier,
L. Montagnier, and U. Hazan.
1990.
A microtransfection method using luciferase gene for the study of human immunodeficiency virus long terminal repeat activity.
Gene
88:197-205[Medline].
|
| 43.
|
Signoret, N.,
J. Oldridge,
A. Pelchen-Matthews,
P. J. Klasse,
T. Tran,
L. F. Brass,
M. M. Rosenkilde,
T. W. Schwartz,
W. Holmes,
W. Dallas,
M. A. Luther,
T. N. C. Wells,
J. A. Hoxie, and M. Marsh.
1997.
Phorbol esters and SDF-1 induce rapid endocytosis and down modulation of the chemokine receptor CXCR4.
J. Cell Biol.
139:651-664[Abstract/Free Full Text].
|
| 44.
|
Sozzani, S.,
S. Ghezzi,
G. Iannolo,
W. Luini,
A. Borsatti,
N. Polentarutti,
A. Sica,
M. Locati,
C. Mackay,
T. N. Wells,
P. Biswas,
E. Vicenzi,
G. Poli, and A. Mantovani.
1998.
Interleukin 10 increases CCR5 expression and HIV infection in human monocytes.
J. Exp. Med.
187:439-444[Abstract/Free Full Text].
|
| 45.
|
Tachibana, K.,
S. Hirota,
H. Iizasa,
H. Yoshida,
K. Kawabata,
Y. Kataoka,
Y. Kitamura,
K. Matsushima,
N. Yoshida,
S. Nishikawa,
T. Kishimoto, and T. Nagasawa.
1998.
The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract.
Nature
393:591-594[Medline].
|
| 46.
|
Ward, S. G.,
K. Bacon, and J. Westwick.
1998.
Chemokines and T lymphocytes: more than an attraction.
Immunity
9:1-11[Medline].
|
| 47.
|
Zou, Y.,
A. Kottmann,
M. Kuroda,
I. Taniuchi, and D. R. Littman.
1998.
Function of the chemokine receptor CXCR4 in hematopoiesis and in cerebellar development.
Nature
391:595-599.
|
Journal of Virology, May 1999, p. 3608-3615, Vol. 73, No. 5
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Mselle, T. F., Howell, A. L., Ghosh, M., Wira, C. R., Sentman, C. L.
(2009). Human Uterine Natural Killer Cells but Not Blood Natural Killer Cells Inhibit Human Immunodeficiency Virus Type 1 Infection by Secretion of CXCL12. J. Virol.
83: 11188-11195
[Abstract]
[Full Text]
-
Derrien, M., Faye, A., Dolcini, G., Chaouat, G., Barre-Sinoussi, F., Menu, E.
(2005). Impact of the Placental Cytokine-Chemokine Balance on Regulation of Cell-Cell Contact-Induced Human Immunodeficiency Virus Type 1 Translocation across a Trophoblastic Barrier In Vitro. J. Virol.
79: 12304-12310
[Abstract]
[Full Text]
-
Kimura, R., Nishioka, T., Soemantri, A., Ishida, T.
(2005). Allele-specific transcript quantification detects haplotypic variation in the levels of the SDF-1 transcripts. Hum Mol Genet
14: 1579-1585
[Abstract]
[Full Text]
-
Princen, K., Hatse, S., Vermeire, K., Aquaro, S., De Clercq, E., Gerlach, L.-O., Rosenkilde, M., Schwartz, T. W., Skerlj, R., Bridger, G., Schols, D.
(2004). Inhibition of Human Immunodeficiency Virus Replication by a Dual CCR5/CXCR4 Antagonist. J. Virol.
78: 12996-13006
[Abstract]
[Full Text]
-
Roscic-Mrkic, B., Fischer, M., Leemann, C., Manrique, A., Gordon, C. J., Moore, J. P., Proudfoot, A. E. I., Trkola, A.
(2003). RANTES (CCL5) uses the proteoglycan CD44 as an auxiliary receptor to mediate cellular activation signals and HIV-1 enhancement. Blood
102: 1169-1177
[Abstract]
[Full Text]
-
Amara, A., Vidy, A., Boulla, G., Mollier, K., Garcia-Perez, J., Alcami, J., Blanpain, C., Parmentier, M., Virelizier, J.-L., Charneau, P., Arenzana-Seisdedos, F.
(2003). G Protein-Dependent CCR5 Signaling Is Not Required for Efficient Infection of Primary T Lymphocytes and Macrophages by R5 Human Immunodeficiency Virus Type 1 Isolates. J. Virol.
77: 2550-2558
[Abstract]
[Full Text]
-
Marozsan, A. J., Torre, V. S., Johnson, M., Ball, S. C., Cross, J. V., Templeton, D. J., Quinones-Mateu, M. E., Offord, R. E., Arts, E. J.
(2001). Mechanisms Involved in Stimulation of Human Immunodeficiency Virus Type 1 Replication by Aminooxypentane RANTES. J. Virol.
75: 8624-8638
[Abstract]
[Full Text]
-
Lane, B. R., Lore, K., Bock, P. J., Andersson, J., Coffey, M. J., Strieter, R. M., Markovitz, D. M.
(2001). Interleukin-8 Stimulates Human Immunodeficiency Virus Type 1 Replication and Is a Potential New Target for Antiretroviral Therapy. J. Virol.
75: 8195-8202
[Abstract]
[Full Text]
-
Lane, B. R., Strieter, R. M., Coffey, M. J., Markovitz, D. M.
(2001). Human Immunodeficiency Virus Type 1 (HIV-1)-Induced GRO-{alpha} Production Stimulates HIV-1 Replication in Macrophages and T Lymphocytes. J. Virol.
75: 5812-5822
[Abstract]
[Full Text]
-
Sei, S., O'Neill, D. P., Stewart, S. K., Yang, Q.-e., Kumagai, M., Boler, A. M., Adde, M. A., Zwerski, S. L., Wood, L. V., Venzon, D. J., Magrath, I. T.
(2001). Increased Level of Stromal Cell-Derived Factor-1 mRNA in Peripheral Blood Mononuclear Cells from Children with AIDS-related Lymphoma. Cancer Res.
61: 5028-5037
[Abstract]
[Full Text]
-
Fantuzzi, L., Canini, I., Belardelli, F., Gessani, S.
(2001). HIV-1 gp120 Stimulates the Production of {{beta}}-Chemokines in Human Peripheral Blood Monocytes Through a CD4-Independent Mechanism. J. Immunol.
166: 5381-5387
[Abstract]
[Full Text]
-
Rusconi, S., La Seta Catamancio, S., Citterio, P., Bulgheroni, E., Croce, F., Herrmann, S. H., Offord, R. E., Galli, M., Hirsch, M. S.
(2000). Combination of CCR5 and CXCR4 Inhibitors in Therapy of Human Immunodeficiency Virus Type 1 Infection: In Vitro Studies of Mixed Virus Infections. J. Virol.
74: 9328-9332
[Abstract]
[Full Text]
-
Moir, S., Malaspina, A., Li, Y., Chun, T.-W., Lowe, T., Adelsberger, J., Baseler, M., Ehler, L. A., Liu, S., Davey, R. T. Jr., Mican, J. A. M., Fauci, A. S.
(2000). B Cells of HIV-1-Infected Patients Bind Virions through Cd21-Complement Interactions and Transmit Infectious Virus to Activated T Cells. JEM
192: 637-646
[Abstract]
[Full Text]
-
Le Borgne, S., Février, M., Callebaut, C., Lee, S. P., Rivière, Y.
(2000). CD8+-Cell Antiviral Factor Activity Is Not Restricted to Human Immunodeficiency Virus (HIV)-Specific T Cells and Can Block HIV Replication after Initiation of Reverse Transcription. J. Virol.
74: 4456-4464
[Abstract]
[Full Text]
-
Orsini, M. J., Parent, J.-L., Mundell, S. J., Benovic, J. L.
(1999). Trafficking of the HIV Coreceptor CXCR4. ROLE OF ARRESTINS AND IDENTIFICATION OF RESIDUES IN THE C-TERMINAL TAIL THAT MEDIATE RECEPTOR INTERNALIZATION. J. Biol. Chem.
274: 31076-31086
[Abstract]
[Full Text]
-
Moir, S., Lapointe, R., Malaspina, A., Ostrowski, M., Cole, C. E., Chun, T.-W., Adelsberger, J., Baseler, M., Hwu, P., Fauci, A. S.
(1999). CD40-Mediated Induction of CD4 and CXCR4 on B Lymphocytes Correlates with Restricted Susceptibility to Human Immunodeficiency Virus Type 1 Infection: Potential Role of B Lymphocytes as a Viral Reservoir. J. Virol.
73: 7972-7980
[Abstract]
[Full Text]
-
Maeda, K., Yoshimura, K., Shibayama, S., Habashita, H., Tada, H., Sagawa, K., Miyakawa, T., Aoki, M., Fukushima, D., Mitsuya, H.
(2001). Novel Low Molecular Weight Spirodiketopiperazine Derivatives Potently Inhibit R5 HIV-1 Infection through Their Antagonistic Effects on CCR5. J. Biol. Chem.
276: 35194-35200
[Abstract]
[Full Text]